Latest news with #IntegraLifeSciences
Globe and Mail
4 days ago
- Business
- Globe and Mail
Collagen & Gelatin Market worth US$1,671.3 million in 2030 5.8% CAGR
"The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel)" Browse 280 market data Tables and 53 Figures spread through 252 Pages and in-depth TOC on "Collagen & Gelatin Market by Source (Bovine, Porcine, Marine), Application (Orthopedic, Cardiovascular, Dental, Surgical), Competitive Landscape (Company Profile, Market share, Company Evaluation Matrix), End User, and Region - Global Forecast to 2030 The global Collagen & Gelatin Market, valued at US$1,203.9 million in 2024, is forecasted to grow at a robust CAGR of 5.8%, reaching US$1,295.5 million in 2025 and an impressive US$1,671.3 million by 2030. Growing incidence of diabetes, cancer, and chronic diseases; rising demand for advanced wound care products; surge in surgical procedures; increasing use in tissue engineering and regenerative medicine; extensive application of collagen as a drug delivery system are driving the market. Browse in-depth TOC on " Collagen & Gelatin Market" 228 - Tables 44 - Figures 240 - Pages By Based on segment, the collagen & gelatin market is divided into bovine, porcine, and others. The large share of the bovine segment can be attributed to the growing adoption of bovine-derived collagen and gelatin in regenerative medicine. Additionally, the increased usage of biomaterials is primarily due to the biocompatibility and biodegradability properties exhibited by these materials. By Based on application, The collagen market is segmented into orthopaedic, wound care, dental, surgical, cardiovascular, and other applications. In 2024, the orthopaedic application segment accounted for the largest share of the collagen market by applications due to the rising demand for scaffolds and substitutes due to their extensive use in orthopaedic surgeries. This dominance is expected to continue throughout the forecast period due to the rising number of road trauma cases. By geography, the collagen & gelatin market is divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. In 2024, North America held the largest share of the collagen & gelatin market, followed by Europe. Asia Pacific registered the highest CAGR growth within the collagen & gelatin market during the forecast period due to its increasing application for research and clinical diagnostics, adoption of collagen & gelatin for transplantation-associated research, and government initiatives and industrial collaboration. The report profiles key players such as Integra LifeSciences Corporation (US), Smith+Nephew plc (UK), DSM-Firmenich (Netherlands), Nitta Gelatin Inc. (Japan), Tessenderlo Group (Belgium), Collplant Biotechnologies Ltd. (Israel), Collagen Solutions plc (UK), Regenity (US), Medtronic plc (Ireland), and Solventum (US). INTEGRA LIFESCIENCES (US): Integra LifeSciences leads in the collagen & gelatin market. It operates through two business segments, namely Codman Specialty Surgical and Tissue Technologies. The company offers engineered bovine collagen, bovine dermis, porcine urinary bladder, human amniotic tissue, and resorbable synthetic mesh products through its Tissue Technologies Segment. This segment recorded a decline of 3.3% in 2024 over 2023 due to the impact of the lost revenue related to the Boston product recall, which was partially offset by double-digit growth from BioD and Gentrix and mid-single-digit growth in Integra skin and MediHoney. The company's leading position is attributable to its diversified product portfolio, geographical expansion, and adoption of organic and inorganic growth strategies. For instance, in March 2024, Integra Life Sciences received an US FDA approval to commercialize a dermal regeneration template for repairing scar contractures. SMITH+NEPHEW PLC (UK): Smith+Nephew is one of the leading players in the collagen & gelatin market due to its robust portfolio, including innovative collagen-based scaffolds and collagenase-based enzymatic debridement agents. The company operates through three business segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers collagen and gelatin products through its advanced wound management business segment. Additionally, the company's strong global presence, strategic partnerships, and commitment to customer-centric solutions position it as a key player in the competitive collagen and gelatin space. The company possesses a strong geographical presence with a broad range of distribution networks to solidify its leadership in the collagen and gelatin market. The advanced wound management business segment of Smith+Nephew has experienced a positive growth rate of 4.7% in the year 2024 and maintained positive momentum in 2024, with growth accelerating toward the end of the year. For more information, Inquire Now!
Associated Press
06-05-2025
- Business
- Associated Press
Attention Long-Term Shareholders of Integra LifeSciences Holdings Corporation (NASDAQ
PHILADELPHIA, May 06, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corp. (NASDAQ: IART): Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them. Learn more or join at: . Contact Joshua H. Grabar at [email protected] , or call 267-507-6085. WHY: An underlying securities fraud class action complaint alleges that Integra, via certain of his officers and directors, repeatedly touted that it was on track to grow SurgiMend's market by obtaining FDA approval for use in post-mastectomy reconstruction, yet on May 23, 2023, the Company was forced to announce a 'recall' of all products manufactured at its Boston Facility between March 1, 2018 and May 22, 2023. Integra LifeSciences explained that it had determined that the Boston Facility deviated from good manufacturing practices in testing for bacterial endotoxin and allowed the release of products with unsafe levels of endotoxins. As a result of the recall and manufacturing shutdown, the Company revised its guidance for the second quarter of 2023, lowering its revenue expectations by and disclosed that it expected to take a $22 million impairment due to the inventory write-off. WHAT TO DO NOW: Current Integra LifeSciences shareholders who have held Integra LifeSciences shares since on or before March 11, 2019, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. If you would like to learn more about this matter, you are encouraged to visit , contact Joshua H. Grabar at [email protected] , or call us at 267-507-6085. $IART #IntegraLifeSciences Mercury Systems, Inc. (NASDAQ: MRCY) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of Mercury Systems, Inc. (NASDAQ: MRCY) shareholders as securities fraud class action complaint partially survives motion to dismiss. . Current Mercury Systems shareholders who have held shares since prior to February 3, 2021, can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to them whatsoever. To learn more or join click here: , contact Joshua H. Grabar at [email protected] , or call us at 267-507-6085. WHY: A recently filed securities fraud class action complaint has now partially survived defendants' attempts to dismiss that complaint. The underlying complaint alleges that Mercury Systems, through certain of its officers and directors, used acquisitions and improper revenue recognition practices to mask its inability to grow organically. The complaint further alleges that Defendants repeatedly misled investors to believe that their growth was organic by misrepresenting several elements of Mercury's business, including by hiding that Mercury had switched from 'point-in-time' to 'long-term contracts' in order to improperly boost reported revenues and that several of Mercury's projects were in significant distress, including projects related to Mercury's acquisition of Physical Optics Corporation. Finally, the Complaint alleges Mercury also lied to investors about its strategic growth initiative, 1MPACT, which was designed to improve profit margins but unbeknownst to investors was used to disguise regular expenses as restructuring costs, enabling Mercury to claim that recurring expenses were one-time costs. On February 20, 2025, a Federal Court determined that certain key allegations in the plaintiff's underlying securities fraud class action complaint were adequately pleaded to survive defendants attempts to dismiss the complaint. WHAT YOU CAN DO NOW: If you have held Mercury Systems shares since prior to February 3, 2021, and would like to learn more about this matter, you are encouraged to visit , contact Joshua H. Grabar at [email protected] , or call us at 267-507-6085. $MRCY #MercurySystems Monolithic Power Systems, Inc. (NASDAQ: MPWR): Current Monolithic Power Systems, Inc. (NASDAQ: MPWR) shareholders who have held shares of the Company's stock since prior to February 8, 2024, can seek corporate reforms, the return of funds back to the company, and potentially a court approved incentive award if appropriate, at no cost to them whatsoever. Click here to learn more or join: , contact Joshua Grabar at [email protected] , or call us at 267-507-6085. WHY: A recently filed securities fraud class action Complaint alleges that, Monolithic Power Systems, Inc. (NASDAQ: MPWR), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) Monolithic's voltage regulator modules and power management integrated circuits were suffering from significant performance and quality control issues; (ii) these defects had, in turn, negatively impacted the performance of certain products offered by Nvidia in which such products were used; (iii) Monolithic had failed to adequately address and resolve known issues affecting the performance of the power management solutions Monolithic supplied to Nvidia; (iv) Monolithic's relationship with Nvidia - the Company's most important customer - had been irreparably damaged due to the significant performance and quality control problems affecting the products it supplied to Nvidia and Monolithic's failure to adequately address such issues; and (v) as a result of the above, Monolithic was acutely exposed to material undisclosed risks of significant business, financial, and reputational harm. WHAT YOU CAN DO NOW: If you have held Monolithic (NASDAQ: MPWR) shares since prior to February 8, 2024, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. Please visit , contact Joshua Grabar at [email protected] , or call us at 267-507-6085. #MonolithicPower #MPWR $MPWR Virtu Financial Inc. (NASDAQ: VIRT) Class Action Survives Motion to Dismiss: A federal securities fraud class action complaint alleging that Virtu Financial Inc. (NASDAQ: VIRT), and certain of its officers failed to disclose to investors that it had improper safeguards in place for sensitive trader information, has survived a motion to dismiss. Virtu shareholders who have continuously held Virtu shares since prior to November 7, 2018, can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to them whatsoever. Learn more or join by clicking , contact Joshua H. Grabar at [email protected] , or call 267-507-6085. WHY: A securities fraud class action complaint alleges that Virtu Financial (NASDAQ: VIRT), via certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) the Company maintained deficient policies and procedures with respect to its information access barriers; (ii) accordingly, Virtu had overstated the Company's operational and technological efficacy as well as its capacity to block the exchange of confidential information between departments or individuals within the Company; (iii) the foregoing deficiencies increased the likelihood that the Company would be subject to enhanced regulatory scrutiny; and (iv) as a result, Defendants' public statements were materially false and/or misleading at all relevant times. On March 17, 2025, a federal Court determined that key allegations were sufficiently pled to survive defendants' motion to dismiss. According to the Court's Order, 'essentially anyone at Virtu, including its proprietary traders' could directly access this material non-public information from at least January 2018 through April 2019, and to do so, Virtu traders only needed to use a 'widely known and frequently shared username and password.' WHAT YOU SHOULD DO NOW: If you are a current Virtu shareholder who has held Virtu stock since on or before November 7, 2018, you can seek corporate reforms, the return of funds spent defending litigation back to the company, and a court approved incentive award, at no cost to you whatsoever. If you would like to learn more about this matter, you are encouraged visit , contact Joshua H. Grabar at [email protected] or call 267-507-6085. $VIRT #VirtuFinancial Attorney Advertising Disclaimer Contact: Joshua H. Grabar, Esq. Grabar Law Office One Liberty Place 1650 Market Street, Suite 3600 Philadelphia, PA 19103 Tel: 267-507-6085 Email: [email protected]
Yahoo
05-05-2025
- Business
- Yahoo
Integra LifeSciences (NASDAQ:IART) Reports Q1 In Line With Expectations But Quarterly Revenue Guidance Significantly Misses Expectations
Medical device company Integra LifeSciences (NASDAQ:IART) met Wall Street's revenue expectations in Q1 CY2025, with sales up 3.7% year on year to $382.7 million. On the other hand, next quarter's revenue guidance of $395 million was less impressive, coming in 5.3% below analysts' estimates. Its non-GAAP profit of $0.41 per share was 4.9% below analysts' consensus estimates. Is now the time to buy Integra LifeSciences? Find out in our full research report. Revenue: $382.7 million vs analyst estimates of $381.2 million (3.7% year-on-year growth, in line) Adjusted EPS: $0.41 vs analyst expectations of $0.43 (4.9% miss) Adjusted EBITDA: $63.61 million vs analyst estimates of $65.34 million (16.6% margin, 2.7% miss) The company reconfirmed its revenue guidance for the full year of $1.68 billion at the midpoint Management lowered its full-year Adjusted EPS guidance to $2.24 at the midpoint, a 8.9% decrease Operating Margin: -4%, down from 11% in the same quarter last year Free Cash Flow was -$40.18 million, down from $291,000 in the same quarter last year Organic Revenue fell 3.5% year on year (-2.5% in the same quarter last year) Market Capitalization: $1.30 billion 'We remain laser focused on strengthening our quality systems, improving supply reliability, and driving operational excellence. There remains significant work ahead, but we are continuing to put the processes and people in place to execute on our comprehensive Compliance Master Plan and build a foundation for sustainable performance. With the launch of our Transformation and Program Management Office and the addition of key leadership, including in global operations, we are driving improved accountability and execution across the enterprise to deliver meaningful long-term value for patients, customers, and shareholders,' said Mojdeh Poul, president and CE). Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ:IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments. A company's long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Unfortunately, Integra LifeSciences's 1.4% annualized revenue growth over the last five years was tepid. This fell short of our benchmarks and is a tough starting point for our analysis. We at StockStory place the most emphasis on long-term growth, but within healthcare, a half-decade historical view may miss recent innovations or disruptive industry trends. Integra LifeSciences's annualized revenue growth of 2% over the last two years aligns with its five-year trend, suggesting its demand was consistently weak. Integra LifeSciences also reports organic revenue, which strips out one-time events like acquisitions and currency fluctuations that don't accurately reflect its fundamentals. Over the last two years, Integra LifeSciences's organic revenue averaged 1.6% year-on-year declines. Because this number is lower than its normal revenue growth, we can see that some mixture of acquisitions and foreign exchange rates boosted its headline results. This quarter, Integra LifeSciences grew its revenue by 3.7% year on year, and its $382.7 million of revenue was in line with Wall Street's estimates. Company management is currently guiding for a 5.5% year-on-year decline in sales next quarter. Looking further ahead, sell-side analysts expect revenue to grow 4.5% over the next 12 months. While this projection implies its newer products and services will fuel better top-line performance, it is still below average for the sector. Unless you've been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) stock benefiting from the rise of AI. Click here to access our free report one of our favorites growth stories. Operating margin is a key measure of profitability. Think of it as net income - the bottom line - excluding the impact of taxes and interest on debt, which are less connected to business fundamentals. Integra LifeSciences has managed its cost base well over the last five years. It demonstrated solid profitability for a healthcare business, producing an average operating margin of 15.2%. Looking at the trend in its profitability, Integra LifeSciences's operating margin decreased by 9.3 percentage points over the last five years. This performance was caused by more recent speed bumps as the company's margin fell by 11.1 percentage points on a two-year basis. We're disappointed in these results because it shows its expenses were rising and it couldn't pass those costs onto its customers. This quarter, Integra LifeSciences generated an operating profit margin of negative 4%, down 15 percentage points year on year. This contraction shows it was less efficient because its expenses grew faster than its revenue. Revenue trends explain a company's historical growth, but the long-term change in earnings per share (EPS) points to the profitability of that growth – for example, a company could inflate its sales through excessive spending on advertising and promotions. Sadly for Integra LifeSciences, its EPS declined by 1.2% annually over the last five years while its revenue grew by 1.4%. This tells us the company became less profitable on a per-share basis as it expanded due to non-fundamental factors such as interest expenses and taxes. We can take a deeper look into Integra LifeSciences's earnings to better understand the drivers of its performance. As we mentioned earlier, Integra LifeSciences's operating margin declined by 9.3 percentage points over the last five years. This was the most relevant factor (aside from the revenue impact) behind its lower earnings; taxes and interest expenses can also affect EPS but don't tell us as much about a company's fundamentals. In Q1, Integra LifeSciences reported EPS at $0.41, down from $0.55 in the same quarter last year. This print missed analysts' estimates. Over the next 12 months, Wall Street expects Integra LifeSciences's full-year EPS of $2.42 to grow 7.2%. It was good to see Integra LifeSciences narrowly top analysts' organic revenue expectations this quarter. On the other hand, its full-year EPS guidance missed significantly and its revenue guidance for next quarter fell short of Wall Street's estimates. Overall, this quarter could have been better. The stock traded down 1.6% to $16.55 immediately after reporting. Integra LifeSciences's latest earnings report disappointed. One quarter doesn't define a company's quality, so let's explore whether the stock is a buy at the current price. The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it's free. Sign in to access your portfolio
Yahoo
05-05-2025
- Business
- Yahoo
Why Integra LifeSciences (IART) Shares Are Getting Obliterated Today
Shares of medical device company Integra LifeSciences (NASDAQ:IART) fell 28.5% in the morning session after the company reported weak first-quarter 2025 results, which included a significant miss on full-year EPS guidance and the next quarter's revenue outlook. Segment results were mixed as key businesses like Neurosurgery and Tissue Technologies declined, pulled down by inventory issues and slower ordering patterns. Along with rising costs, margins and profit were dragged down as EBITDA and EPS both dropped, and cash flow was in the red. Even though management kept the full-year sales target, they had to cut their profit outlook due to tariff concerns. Overall, this quarter could have been better. The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Integra LifeSciences? Access our full analysis report here, it's free. Integra LifeSciences's shares are very volatile and have had 21 moves greater than 5% over the last year. But moves this big are rare even for Integra LifeSciences and indicate this news significantly impacted the market's perception of the business. The biggest move we wrote about over the last year was 2 months ago when the stock gained 13.6% on the news that the company reported strong fourth quarter 2024 results that beat analysts' EPS and EBITDA expectations. On the other hand, its full-year revenue and EPS guidance fell short of Wall Street's estimates. The company expects continued demand for its portfolio but flagged potential headwinds, including intermittent product shipping holds. Overall, while this was a strong quarter with solid execution, cautious guidance suggests near-term uncertainty. Integra LifeSciences is down 45.8% since the beginning of the year, and at $12.48 per share, it is trading 60.8% below its 52-week high of $31.86 from June 2024. Investors who bought $1,000 worth of Integra LifeSciences's shares 5 years ago would now be looking at an investment worth $240.51. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we've identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Sign in to access your portfolio
Yahoo
18-04-2025
- Business
- Yahoo
Integra LifeSciences to Host First Quarter 2025 Financial Results Conference Call on May 5, 2025
PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET. A live webcast will be available on the Investors section of the Company's website at For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company's website following the call. About Integra LifeSciences At Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic and regenerative care. We offer a comprehensive portfolio of high quality, leadership brands. For the latest news and information about Integra and its products, please visit Investor Relations:Chris Ward(609) Media Contact:Laurene Isip(609) Integra LifeSciences Holdings CorporationSign in to access your portfolio
